Cargando…

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma

Sarcopenia, defined as decreased muscle mass and strength, can be evaluated by a computed tomography (CT) examination and might be associated with reduced survival in patients with carcinoma. The prognosis of patients with metastatic pancreatic carcinoma is poor. The FOLFIRINOX (a combination of 5-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lellouche, Lisa, Barat, Maxime, Pellat, Anna, Leroux, Juliette, Corre, Felix, Hallit, Rachel, Assaf, Antoine, Brezault, Catherine, Dhooge, Marion, Soyer, Philippe, Coriat, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056206/ https://www.ncbi.nlm.nih.gov/pubmed/36983212 http://dx.doi.org/10.3390/jcm12062211

Ejemplares similares

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
por: Falette Puisieux, Manon, et al.
Publicado: (2022)

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
por: Rémond, M.S., et al.
Publicado: (2022)

The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis
por: Jeridi, Dalel, et al.
Publicado: (2022)

Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
por: Lellouche, Lisa, et al.
Publicado: (2021)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
por: Palmieri, Lola-Jade, et al.
Publicado: (2020)

Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients
por: Dréanic, Johann, et al.
Publicado: (2015)

Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
por: Pellat, Anna, et al.
Publicado: (2021)

Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
por: Marchese, Ugo, et al.
Publicado: (2022)

Outcomes of endoscopic mucosal resection for large superficial non-ampullary duodenal adenomas
por: Amoyel, Maxime, et al.
Publicado: (2022)

Updates on the Treatment of Pancreatic Diseases: Focus on Surgery, Electrochemotherapy and Rituximab
por: Coriat, Romain, et al.
Publicado: (2022)

Airborne transmission of SARS‐Cov2: What consequences for digestive endoscopy?
por: Chaussade, Stanislas, et al.
Publicado: (2023)

A new system to prevent SARS-CoV-2 and microorganism air transmission through the air circulation system of endoscopes
por: Chaussade, Stanislas, et al.
Publicado: (2022)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment
por: Pellat, Anna, et al.
Publicado: (2022)

Self-expandable metal stent through the tumor to treat an intestinal obstruction due to pancreatic squamous cell carcinoma
por: Soliman, Heithem, et al.
Publicado: (2017)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer
por: Pellat, Anna, et al.
Publicado: (2022)

Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
por: Barat, Maxime, et al.
Publicado: (2021)

Clinical impact of routine CT esophagogram after peroral endoscopic myotomy (POEM) for esophageal motility disorders
por: Chartier, Marion, et al.
Publicado: (2021)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
por: Pellat, Anna, et al.
Publicado: (2020)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

Endoscopic management of non-ampullary duodenal adenomas
por: Amoyel, Maxime, et al.
Publicado: (2022)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Impact of a dedicated multidisciplinary meeting on the management of superficial cancers of the digestive tract
por: Dermine, Solène, et al.
Publicado: (2018)

Results of the national organised colorectal cancer screening program with FIT in Paris
por: Pellat, Anna, et al.
Publicado: (2018)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
por: Stein, Stacey M, et al.
Publicado: (2016)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Organ Preservation after Endoscopic Resection of Early Esophageal Cancer with a High Risk of Lymph Node Involvement
por: Dermine, Solène, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pi7dukuk9eeheuobttijbfsdns